Novel recombinant sabin type 1 poliovirus vector and vaccine against poliovirus
AssigneeCreagene Inc.
InventorsYong Soo Bae, Sang Goo Lee, Hye Jeong, Dong Lee, Ki Kim, Dae Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide sequence encoding an additional polioviral cleavage site; and (c) a nucleotide sequence of a conformational epitope encoding a VP1 neutralizing epitope of poliovirus type 2 or 3 and linked to the nucleotide sequence of (b).
Claims20
A recombinant Sabin type 1 poliovirus vector, which comprises:
- (a) a genomic nucleotide sequence of a Sabin type 1 poliovirus;
- (b) a nucleotide sequence encoding an additional polioviral cleavage site;
- and
- (c) a nucleotide sequence encoding a conformational epitope encoding comprising a VP1 neutralizing epitope of poliovirus type 2 or 3 and linked to the nucleotide sequence of (b), wherein said conformational epitope comprising a VP1 neutralizing epitope of poliovirus type 2 is the amino acid 65-202 of SEQ ID NO:1, and wherein said conformational epitope comprising a VP1 neutralizing epitope of poliovirus type 3 is the amino acid 63-200 of SEQ ID NO:2, and wherein said nucleotide sequence encoding the conformational epitope is less than 450 bp.
(canceled)
(canceled)
(canceled)
(canceled)
20-24. (canceled)
Dependencies are inferred from the claim text.